Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 13/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | GRK2 | P25098 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1956753 | 0.78 | AKT2 (0.50) | ROCK2ROCK1PDK2ERN1AKT1 | |
| SCHEMBL31662985 | 0.76 | IDO1 (0.40) | DRD1 | |
| SCHEMBL31190896 | 0.76 | PDK2 (0.41) | ROCK2ROCK1PDK2DRD1ERN1 | |
| SCHEMBL5083611 | 0.71 | DRD1 (0.47) | DRD1ERN1 | |
| SCHEMBL16793384 | 0.70 | ERN1 (0.48) | DRD1ERN1 | |
| SCHEMBL18124516 | 0.68 | TSHR (0.48) | DRD1ERN1 | |
| SCHEMBL3927888 | 0.68 | CA1 (0.61) | DRD1ERN1 | |
| SCHEMBL4132573 | 0.67 | SRC (0.58) | DRD1ERN1 | |
| SCHEMBL3273244 | 0.65 | CA1 (0.40) | DRD1 | |
| SCHEMBL24802714 | 0.64 | TDP1 (0.44) | ROCK2ROCK1ERN1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025149498-A1 | BENZYLPIPERIDINE DERIVATIVES AS TRP4 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | WO | disclosed |